Literature DB >> 12617718

Improvement after verteporfin therapy.

Rajiv Anand, Neil M Bressler, Susan B Bressler, Todd E Gray, Patricia Harvey, Laurie Haynes, John M Koester, Kelly S Manos, Joan W Miller, Sandra Murphy, Al Reaves, Michel Sickenberg, Lawrence J Singerman, Andrew Strong, Michael Stur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12617718     DOI： 10.1001/archopht.121.3.415

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  5 in total

1.  Deficits in the electroretinogram in neovascular age-related macular degeneration and changes during photodynamic therapy.

Authors:  Alison M Mackay; Malcolm C Brown; Richard P Hagan; Anthony C Fisher; Ian Grierson; Simon P Harding
Journal:  Doc Ophthalmol       Date:  2007-08-02       Impact factor: 2.379

2.  Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration.

Authors:  Michael Voelker; Faik Gelisken; Focke Ziemssen; Joachim Wachtlin; Salvatore Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-12       Impact factor: 3.117

Review 3.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis.

Authors:  Rose Gilbert; Ahmed Al-Janabi; Oren Tomkins-Netzer; Sue Lightman
Journal:  Porto Biomed J       Date:  2017-03-01

5.  Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).

Authors:  Faik Gelisken; Michael Voelker; Rainer Schwabe; Dorothea Besch; Sabine Aisenbrey; Peter Szurman; Salvatore Grisanti; Volker Herzau; Karl U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 3.535
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.